Cullinan Therapeutics, Inc. Common Stock

CGEMNASDAQ • USD
ThemeHealthcare - Oncology›Immunotherapy & Immuno-Oncology
17.95 USD
↗ 0.34 (1.93%)AT CLOSE (11:59 AM EDT)
18.14
↗ 0.19 (1.03%)
POST MARKET (AS OF 07:34 PM EDT)
Post Market
AS OF 07:34 PM EDT
18.14
↗ 0.19 (1.03%)
🔴Market: CLOSED

Cullinan Therapeutics, Inc. Common Stock (CGEM) is currently trading at $17.97. There is a divergence between signals — technical indicators rate "Strong Buy" but underlying fundamentals lean "Sell". Notable factors include a robust Altman Z-Score, a weak Piotroski F-Score of 0/9, negative Return on Equity, a bullish Golden Cross on the moving averages and bullish moving average alignment. The stock looks compelling on valuation, with multiples below sector averages across P/E, P/B, and EV/EBITDA.

Technical & fundamental data as of Aug 6, 2026.

Open?$17.67
High?$17.99
Low?$17.06
Prev. Close?$17.61
Volume?595.4K
Avg. Volume?731.9K
VWAP?$17.62
Rel. Volume?0.81x
Bid / Ask
Bid?$15.47 × 100
Ask?$21.23 × 100
Spread?$5.76
Midpoint?$18.35
Valuation & Ratios
Market Cap?1.1B
Shares Out?61.5M
Float?52.8M
Float %?85.9%
P/E Ratio?N/A
P/B Ratio?2.96
EPS?-$3.18
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.
Themes
Healthcare - Oncology›Immunotherapy & Immuno-OncologyBiotech - Drug Development›Immunology & Autoimmune
Employees
109
Market Cap
1.1B
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Website
www.cullinantherapeutics.com
Listed
2021-01-08
Address
ONE MAIN STREET
CAMBRIDGE, MA 02142
Phone: 617-410-4650
Technical OutlookStrong Buy
Strong SellNeutralStrong Buy
Long-Term (Tide)?▲ Bullish(+2/3)
Medium-Term (Wave)?▲ Bullish(+1/3)
Short-Term (Ripple)?▲ Bullish(+3/3)
MA Alignment?Golden Alignment
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
3
Z-Score?
100
Momentum?
50
Short Sent.?
19
Piotroski F-Score?0/9Weak
Altman Z-Score?14.43Safe
Confidence?45%Low
Full Fundamental Analysis →
Short InterestVery High
Short % of Float?19.49%High
Short Interest?10.3M
Days to Cover?15.2
Free Float52.8M
Avg Daily Volume675.8K
Settlement Date2026-07-15
Financial Health
Current Ratio?10.28Strong
Quick Ratio?10.28Strong
Cash Ratio?2.14Strong
Debt/Equity?0.00Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score
100/100
P/E?
N/A▾
P/B?
Peers
100
S&P
56
2.96CHEAP▾
P/S?
N/A▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-4.2CHEAP▾
EV/Sales?
N/A▾
Returns & Efficiency
ROE?
S&P
3
-53.3%WEAK▾
ROA?
S&P
3
-48.4%WEAK▾
Cash Flow & Enterprise
FCF?$-178689000
Enterprise Value?$1.0B
Fundamentals ratios updated end of day
MarketsMoversWatchlist